Clinical Trials Logo
  1. Home
  2. Human Influenza
  3. NCT01879540

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza Clinical Trial

Official title:
A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad®) in Healthy Adults ≥65 Years of Age

Clinical Trial Summary

The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014 Northern Hemisphere, in adults ≥65 years of age.

For the immunogenicity endpoints the antibody response to each influenza vaccine antigen, will be measured by means of Single Radial Hemolysis (SRH) or Hemagglutination Inhibition (HI) at approximately 21 days post immunization.

The vaccine composition will be based on the World Health Organization (WHO) recommended influenza strains for 2013/2014 Northern Hemisphere.

The results of this study are intended to support the use of this vaccine in future influenza seasons if the recommended vaccine composition remains the same, in compliance with the requirements of the current European Union (EU) recommendations for clinical trials related to yearly licensing of influenza vaccines.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01879540
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date July 2013
Completion date August 2013
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01690637 - Panama and El Salvador Children's Oseltamivir Study Phase 4
Completed NCT03572491 - Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine Phase 3
Recruiting NCT04487041 - Tfh Dysfunction in HIV and Aging Phase 4
Completed NCT02387294 - Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents Phase 3
Completed NCT02600585 - Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults N/A
Completed NCT02398097 - Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects Phase 4
Completed NCT01511744 - Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine Phase 4
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT01677702 - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization N/A
Active, not recruiting NCT01096225 - Immunogenicity Study of S-OIV H1N1 Influenza Vaccine N/A
Completed NCT00880659 - Bangladesh Secondary Transmission Handwashing Protocol Phase 2
Completed NCT01879553 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above Phase 2
Completed NCT01636102 - Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Phase 2
Completed NCT01651104 - Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects Phase 2
Completed NCT03448705 - Safety of 4Fluart ID Suspension for Injection in Adult Subjects Phase 1
Completed NCT02478905 - Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting N/A
Recruiting NCT04431050 - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Completed NCT01568788 - Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine N/A
Completed NCT05155319 - Universal Influenza A Vaccine in Healthy Adults Phase 1
Completed NCT01885117 - Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above Phase 3